CSIMarket
 


Kinnate Biopharma Inc   (KNTE)
Other Ticker:  
 

Kinnate Biopharma Inc 's Working Capital Ratio

KNTE's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 10.8 a new company low.

Within Major Pharmaceutical Preparations industry 89 other companies have achieved higher Working Capital Ratio than Kinnate Biopharma Inc in third quarter 2023. While Working Capital Ratio total ranking has improved so far during the III Quarter 2023 to 304, from total ranking in the second quarter 2023 at 404.

Explain Working Capital Ratio
How much in Current Assets KNTE´s has?
What is the value of KNTE´s Current Liabilities?


KNTE Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 2.81 % 37.59 % 32.95 % 38.59 % 48.98 %
Y / Y Current Assets Change -34.79 % -29.4 % -25.4 % -10.77 % 0.18 %
Working Capital Ratio MRQ 10.8 11.96 11.31 13.45 17.02
KNTE's Total Ranking # 304 # 404 # 416 # 227 # 321
Seq. Current Liabilities Change 0.01 % -13.12 % 5.76 % 11.89 % 33.84 %
Seq. Current Assets Change -9.7 % -8.13 % -11.07 % -11.62 % -2.23 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 90
Healthcare Sector # 145
Overall Market # 304


Working Capital Ratio Statistics
High Average Low
31.09 18.53 10.8
(Jun 30 2021)   (Sep 30 2023)




Financial Statements
Kinnate Biopharma Inc 's Current Liabilities $ 16 Millions Visit KNTE's Balance sheet
Kinnate Biopharma Inc 's Current Assets $ 170 Millions Visit KNTE's Balance sheet
Source of KNTE's Sales Visit KNTE's Sales by Geography


Cumulative Kinnate Biopharma Inc 's Working Capital Ratio

KNTE's Working Capital Ratio for the trailling 12 Months

KNTE Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 2.81 % 37.59 % 32.95 % 38.59 % 48.98 %
Y / Y Current Assets TTM Growth -34.79 % -29.4 % -25.4 % -10.77 % 0.18 %
Working Capital Ratio TTM 11.89 13.33 15.52 17.95 20.1
Total Ranking TTM # 3717 # 3891 # 4002 # 2250 # 138
Seq. Current Liabilities TTM Growth 0.01 % -13.12 % 5.76 % 11.89 % 33.84 %
Seq. Current Assets TTM Growth -9.7 % -8.13 % -11.07 % -11.62 % -2.23 %


  News about Kinnate Biopharma Inc Working Capital Ratio

Kinnate Biopharma Inc Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 - Kinnate Biopharma Inc. (Nasdaq: KNTE), a clinical-stage precision oncology company, and Pierre Fabre Mdicament, SAS (Pierre Fabre Laboratories), a global player in oncology, have announced their agreement to the sale of Kinnate's investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets. This sale of global rights marks a significant development in Kinnate's strategic exploration of alternatives.
Kinnate Biopharma Inc., known for its innovative approaches in precision oncology, has made headway in the field of cancer therapeutics. Through the sale of exarafenib and other pan-RAF program assets, Kinnate aims to leverage the expertise and global reach of Pierre Fabre Laboratories to further advance the development and commercialization of this promising precision medicine.


On the trailing twelve months basis Due to rise in Current Liabilities in the III Quarter 2023 to $15.77 millions, cumulative Working Capital Ratio decreased to 11.89 below the average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 474 other companies have achieved higher Working Capital Ratio than Kinnate Biopharma Inc . While Working Capital Ratio overall ranking has improved so far to 3717, from total ranking during the twelve months ending second quarter 2023 at 3891.

Explain Working Capital Ratio
How much in Current Assets KNTE´s has?
What is the value of KNTE´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 475
Healthcare Sector # 986
Within the Market # 3717


trailing twelve months Working Capital Ratio Statistics
High Average Low
23.89 18.56 11.89
(Dec 31 2021)   (Sep 30 2023)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Viking Therapeutics Inc   29.14 $ 381.300  Millions$ 13.086  Millions
Atossa Therapeutics Inc   28.35 $ 97.648  Millions$ 3.444  Millions
Karuna Therapeutics Inc   27.88 $ 1,365.397  Millions$ 48.968  Millions
Disc Medicine Inc   25.96 $ 374.263  Millions$ 14.416  Millions
Belite Bio Inc  24.76 $ 89.940  Millions$ 3.633  Millions
Janux Therapeutics Inc   24.55 $ 355.195  Millions$ 14.471  Millions
Gh Research Plc  24.49 $ 164.089  Millions$ 6.701  Millions
Bright Minds Biosciences Inc   24.26 $ 5.218  Millions$ 0.215  Millions
Design Therapeutics Inc   23.77 $ 294.543  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.67 $ 5.235  Millions$ 0.221  Millions
Diamedica Therapeutics Inc   22.91 $ 47.886  Millions$ 2.090  Millions
Terns Pharmaceuticals Inc   22.38 $ 270.455  Millions$ 12.087  Millions
Tyra Biosciences Inc   22.14 $ 224.630  Millions$ 10.147  Millions
Cyteir Therapeutics Inc   21.89 $ 130.643  Millions$ 5.969  Millions
Ars Pharmaceuticals Inc   21.87 $ 244.466  Millions$ 11.180  Millions
Eledon Pharmaceuticals Inc   21.73 $ 62.991  Millions$ 2.899  Millions
Astria Therapeutics inc   21.53 $ 191.466  Millions$ 8.894  Millions
Xenon Pharmaceuticals Inc   21.46 $ 531.008  Millions$ 24.744  Millions
Sagimet Biosciences inc   20.79 $ 102.816  Millions$ 4.946  Millions
Acasti Pharma Inc   20.68 $ 28.887  Millions$ 1.397  Millions
Akero Therapeutics Inc   20.25 $ 575.979  Millions$ 28.447  Millions
Tenax Therapeutics Inc   19.73 $ 11.883  Millions$ 0.602  Millions
Mineralys Therapeutics Inc   19.59 $ 265.375  Millions$ 13.543  Millions
Pliant Therapeutics Inc   19.50 $ 534.335  Millions$ 27.395  Millions
Stoke Therapeutics Inc   19.47 $ 230.019  Millions$ 11.811  Millions
Eqrx Inc   19.38 $ 1,235.139  Millions$ 63.726  Millions
Ideaya Biosciences Inc   19.37 $ 482.182  Millions$ 24.893  Millions
Pmv Pharmaceuticals Inc   19.16 $ 205.296  Millions$ 10.716  Millions
Savara Inc   18.98 $ 170.096  Millions$ 8.963  Millions
Medicinova Inc   18.92 $ 52.996  Millions$ 2.802  Millions

Date modified: 2023-11-12T10:02:19+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com